The association between severe deficiency of alpha-1 antitrypsin and early-onset pulmonary emphysema has been known for several decades (1). Alpha-1 antitrypsin is encoded by the SERPINA1 gene, and the most common genetic variants causing deficiency are termed S and Z. The molecular basis of the deficiency is the abnormal folding, polymerization, and retention of the variant proteins in the endoplasmic reticulum of hepatocytes (2). The Z variant causes a change in the amino acid sequence (Glu366Lys) and is associated with plasma levels that are 10-15% of the normal M allele, whereas the S variant (Glu288Val) causes a milder deficiency with plasma levels that are 50-60% of normal.
copies of the Z allele was associated with large decrements in lung function and increased emphysema. Interestingly, a single copy of the Z allele was also associated with adverse effects on the outcome variables, with values intermediate between those for the normal genotype (MM) and ZZ homozygotes. These data support the results of previous studies (6, 7) and confirm that MZ heterozygotes are at increased risk for chronic obstructive pulmonary disease, at least in the presence of heavy smoke exposure.
To achieve a more detailed analysis of the variants, the study participants were categorized into six genotypic groups, separating the effect of the Z allele from the other variants. Using this approach, the authors were able to show that heterozygosity for the Z allele alone was associated with lung function and emphysema in non-Hispanic whites. This result suggests that the disease risk associated with a single copy of the Z allele is not solely a result of compound heterozygotes who have one Z allele and a rare variant in the other copy of SERPINA1. Furthermore, heterozygosity for any rare variant associated with low alpha-1 antitrypsin levels (values in the lowest decile) was associated with emphysema independent of the Z and S alleles.
In the African American and Hispanic groups, there were fewer significant associations, which was likely a result of the lower sample sizes. However, in African-Americans, a single base insertion in the 59 untranslated region of SERPINA1 was associated with low alpha-1 antitrypsin levels and greater functional small airways disease. In vitro data using a reporter gene suggested that the variant alters SERPINA1 gene regulation, and thus may be the causal variant for this novel clinical association.
The study showed that the rare variants and the Z and S alleles considered in aggregate were associated not only with crosssectional outcomes but also with accelerated rate of lung function decline during a 3-year-long period. However, there were no associations of individual variants or subgroups of variants with longitudinal outcomes even in non-Hispanic white patients, indicating that a longer follow-up and/or larger sample size may be needed for these analyses.
One of the main strengths of the study was that a large number of non-Hispanic white patients were sequenced across the entire SERPINA1 coding region. Larger sample sizes for different ethnic groups need to be studied, but the identification of group-specific variants provides a good rationale for performing such studies. Another strength was that the study participants all had significant smoke exposure, thus reducing the potential for lack of penetrance of the variants. The availability of measurements of circulating alpha-1 antitrypsin was an important asset in this study, as it helped guide the interpretation of the genetic association data.
This study illustrates the difficulty in analyzing rare genetic variants: Although there may be significant associations when considered in aggregate (i.e., gene-based burden testing), there are often too few individuals with each variant to test individually with sufficient power. Nevertheless, rare variants are potentially important for the individual patient, and therefore additional largescale studies such as this are warranted. n 
